Ph. Eur. 5.14. GENE TRANSFER MEDICINAL PRODUCTS FOR HUMAN USE

Ph. Eur. 5.14 – Gene transfer medicinal products for human use sets quality expectations for products that deliver genetic material to human cells. It covers viral and non-viral vectors (for in vivo use or for ex vivo cell modification) and focuses on seed-lot/cell-bank strategies, defined manufacturing controls, viral safety, and product specifications to ensure identity, strength, purity/impurities, potency, and safety throughout development.

This general chapter applies to a broad range of gene therapy products, including:

• Non-viral vectors (e.g., plasmid DNA)
• Viral vectors (e.g., Adenovirus, Poxvirus, Retroviridae-derived, and Adeno-Associated Virus (AAV) vectors)
• Genetically modified cells

A robust Quality Management System (QMS) is essential for manufacturing advanced therapies, ensuring product consistency, safety, and efficacy. This system governs the entire lifecycle, from starting materials to long-term stability.

Production must utilize qualified raw materials and be based on well-characterized seed-lot or cell-bank systems. The manufacturing process itself requires tight control over critical parameters, validated aseptic processing to prevent contamination, and comprehensive viral safety testing.

Replication-competent virus testing is mandatory for each vector system (e.g., RCL for lentivirus, RCR for retrovirus, rcAAV for AAV).

Final product release is contingent on meeting predefined specifications for identity, strength (e.g., vector genomes per milliliter, $vg/mL$), purity (both product-related attributes (e.g., empty/full capsids) and process-related impurities (e.g., residual host-cell DNA, proteins, helper virus components, plasmid backbones).), and potency, confirmed by a biologically relevant bioassay. A qualified reference standard underpins all testing. For cell-based products, long-term stability and genetic integrity of the modified cells must also be addressed.